glp-1 and kidney SGLT2 Inhibitors Receptor Agonists in Transplantation: A Systematic Review and Meta-Analysis GLP-1s are back in the

So currently, we dont have enough quality evidence to support the many anti-ageing claims made for peptides

Pediatric peritoneal dialysis and carnitine

Track sleep duration and subjective quality to identify any changes

For manufacturers with pipeline depth, this is manageable

This is just an observational study so there can be no conclusions about the medications being the definitive cause of the decreased risk of Alzheimers and/or dementia. Jennifer Cheng, DO For research next steps, it would be interesting to see the new GLP-1 medications, and effects of the GLP-1s, studied to see if it is definitive, Cheng added

To sign up for limited free access and the national training on July 28th, or request access to the Mployer MCP, please see further details below